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To investigate the association of the Val158Met polymorphism with pain and function out-
comes in women with carpal tunnel syndrome (CTS) who received surgery or manual ther-
apy including desensitization manoeuvres of the central nervous system.
Methods
A pre-planned secondary analysis of a randomized controlled trial investigating the efficacy
of manual therapy including desensitization manoeuvres of the central nervous system vs.
surgery in 120 women with CTS was conducted. Women were randomized to receive 3 ses-
sions of manual therapy (n = 60) or decompression of the carpal tunnel (n = 60). The primary
outcome was intensity of pain (mean pain and the worst pain), and secondary outcomes
included function and symptoms severity subscales of the Boston Carpal Tunnel Question-
naire. Outcomes were assessed at baseline, and 1, 3, 6, and 12 months after the interven-
tion. Rs4680 genotypes were determined after amplifying the Val158Met polymorphism by
polymerase chain reactions. We classified subjects according to their Val158Met polymor-
phism: Val/Val, Val/Met, or Met/Met. The primary aim (treatment group*Val158Met*time)
was examined with repeated measures ANCOVA with intention-to-treat analysis.
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Results
At 12 months, 111 (92%) women completed the follow-up. No interaction was observed
between the Val158Met genotype and any outcome: mean pain intensity (F = 0.60; P =
0.69), worst pain intensity (F = 0.49; P = 0.61), function (F = 0.12; P = 0.88) or symptom
severity (F = 0.01; P = 0.98).
Conclusion
The current clinical trial did not show an association between the Val158Met polymorphism
and changes in pain and function outcomes after either surgery or physical therapy in
women with CTS.
Introduction
Carpal tunnel syndrome (CTS) is a common entrapment neuropathy of the upper extremity
which can cause considerable pain and disability resulting in significantly costs for the society
[1]. It has been reported that the prevalence of CTS in the general population ranges from 6%
to 12% [2].
Management of CTS can be conservative or surgical in nature. There is some controversy
on the optimal treatment strategies for CTS since both approaches are effective, although sur-
gery has shown to be slightly superior than localized conservative treatment at long term [3,4].
It is important to note that individuals undergoing surgery exhibit a higher rate of complica-
tions than those receiving conservative therapy (pooled RR 2.03, 1.28–3.22) [4], which may
explain why several patients with CTS attempt to avoid surgery [5]. It should be also noted
that most studies comparing conservative to surgical interventions have mainly applied local-
ized procedures, e.g., ultrasound, splints, laser, or TENS, mainly focusing to the hand, as the
conservative approach. Although CTS has been traditionally considered a local peripheral neu-
ropathy, there is evidence suggesting that CTS represents a complex pain syndrome presenting
an altered nociceptive pain processing [6,7], and, therefore, therapeutic approaches should
include nociceptive pain rational for proper management of this condition [8].
Supporting the complexity of pain perception is the potential influence of genetic factors.
The catechol-O-methyltransferase (COMT) gene is a potential genetic determinant associated
to nociceptive pain processing [9]; however, its role in neuropathic pain syndromes is scarce
[10]. The Val158Met single-nucleotide polymorphism (rs4680) of the COMT gene is involved
in the metabolic degradation of several neurotransmitters, e.g., dopamine, norepinephrin or
epinephrine [9]. The rs4680 polymorphism leads to a substitution of valine (Val) with methio-
nine (Met) at codon 158 on chromosome 22q11 resulting in different activity levels of the
gene. The presence of a Val allele results in high enzymatic activity whereas the presence of a
Met allele results in low enzymatic activity [9]. In fact, people with the Val/Val genotype
(higher enzymatic activity) exhibit reduced pain sensitivity than those with the Met/Met geno-
type (lower enzymatic activity) suggesting that this genotype could predispose for chronic pain
[9]. The only study investigating a potential genetic influence in CTS found that the presence
of the Met/Met genotype of the Val158Met polymorphism was associated with higher pain
intensity, higher symptoms severity, and lower function in a sample of women with CTS, sug-
gesting a regulating role of Val158Met polymorphism in the phenotypic expression of this con-
dition [11].
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A recent randomized clinical trial compared a physical therapy intervention consisting of
manual therapies including desensitization maneuvers of the central nervous system with sur-
gery on pain and function in women with CTS [12]. The results of this clinical trial showed
that both interventions were similarly effective for improving pain and function at 6 and 12
months [12]. This is the first trial including a multimodal physical therapy approach based on
comprehensive clinical rational of nociceptive pain mechanisms and applied to individuals
with CTS. Since the Val158Met polymorphism modulates the phenotypic expression of CTS
[11], we considered that there may exist a genetic influence on long-term treatment outcomes.
Therefore, the aim of the current study was to investigate the association of the Val158Met
polymorphism with pain and function outcomes in patients with CTS after treatment. We
hypothesized that women with CTS carrying the Met/Met genotype would exhibit worse long-
term treatment outcomes than those carrying the Val/Val or Val/Met genotypes independently
of the intervention received.
Material and methods
This study consisted of a pre-planned secondary analysis of a randomized clinical trial (Clini-
calTrials.gov: NCT01789645) comparing the effectiveness of surgery and physical therapy in
CTS [12]. The study was approved by the Hospital Universitario Fundación Alcorcón (HUFA)
Institutional Review Board (PI01223-HUFA12/14).
Participants
Consecutive women with clinical and electrophysiological findings of CTS were recruited
from a regional Hospital (Madrid, Spain). Patients had to exhibit pain and paresthesia within
the median nerve distribution, increasing symptoms during night, positive Tinel and Phalen
signs, and electro-diagnostic findings of deficits in sensory/motor median nerve conduction
according to American Association of Electrodiagnosis, American Academy of Neurology and
American Physical Medicine and Rehabilitation Academy guidelines [13]. International guide-
lines suggest that a median nerve sensory conduction velocity less than 40 mm/s and a median
nerve distal motor latency greater than 4.20ms are considered as abnormal [13]. Individuals
with minimal (abnormal segmental-comparative tests), moderate (abnormal median nerve
sensory velocity conduction and distal motor latency), or severe (absence of median nerve sen-
sory response and abnormal distal motor latency) CTS were included in this study [14]. Partic-
ipants were excluded if they exhibited: 1, motor or sensory deficits in the ulnar or radial
nerves; 2, age>65 years; 3, surgery or steroid injections in the hand; 4, other pain syndromes
affecting the upper extremity (e.g., cervical radiculopathy); 5, trauma to the neck, shoulder, or
upper extremity; 6, systemic disease causing CTS (e.g. diabetes mellitus, thyroid disease); 7,
other comorbid medical conditions, e.g., rheumatoid arthritis or fibromyalgia; 8, pregnancy; 9,
presence of depressive symptoms (Beck Depression Inventory, BDI-II>8 points); or, 10, male
gender. All participants signed an informed consent prior to the inclusion in the trial. A local
human research committee approved the study project (PI01223-HUFA12/14).
Randomization and interventions
Participants were randomly assigned to receive either physical therapy or surgery. Details on
the randomization procedure have been previously published [12]. As described previously in
detail [12], those patients allocated to the physical therapy group received 3 sessions consisting
of different manual therapies including desensitization maneuvers of the central nervous sys-
tem of 30 min duration, once per week, applied by 3 different therapists with more than 6
years of clinical experience in manual therapy approaches. Briefly, desensitization maneuvers
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included soft tissue techniques targeting the anatomical sites of potential entrapment of the
median nerve (scalene, pectoralis minor, bicipital aponeurosis, pronator teres, transverse car-
pal ligament, and palmar aponeurosis), lateral glides applied to the cervical spine, and tendon
and nerve gliding interventions. In addition, patients were instructed in the tendon and nerve
gliding interventions as homework if necessary, as previously described [12].
Patients allocated to the surgery group underwent open or endoscopic decompression and
release of the carpal tunnel conducted by experienced surgeons with at least 15 years of prac-
tice in hand surgery. Since no particular surgical procedure seems to be more effective, surgery
was based on surgeon’s and patient’s preference [15]. Patients allocated to this group received
the same educational session for performing tendon and nerve gliding exercises as the other
group.
Outcomes
Outcomes were assessed at baseline, and 1, 3, 6, and 12 months after the end of therapy. The
primary outcome was the intensity of hand pain. An 11-point Numerical Pain Rating Scale
(NPRS, 0: no pain; 10: maximum pain) was used to determine the patient’s level of hand pain
and the worst level of pain experienced in the preceding week [16]. The secondary outcomes
were functional status and severity subscales of the Boston Carpal Tunnel Questionnaire
(BCTQ) [17]. As previously described [12], for patients with bilateral symptoms, we assigned
the study hand on the basis of the more self-reported symptomatic hand; if symptoms were
equivalent, the mean pain of both hands was considered.
DNA collection and COMT genotyping
At the beginning of the trial, non-stimulated whole saliva samples were collected from each
participant into collection tubes (passive drooling technique) according to the standardized
procedures as previously described [11]. All subjects had abstained from any kind of vigorous
exercise through the previous week. Those who smoked were asked not to do so from 2 days
before the collection sampling. Patients were asked not to eat or drink or chew gum for 1 hour
before the sampling. Immediately after collection, samples were centrifuged at 3000 rpm for 15
min to obtain the cell sediment and they were stored at -20˚ C until the analysis. We decide to
use saliva instead of blood sampling because saliva collection is a non-invasive, stress-free and
ethic suitable assessment method.
Laboratory technicians were blinded to the subjects’ allocation group. Genomic DNA was
extracted from saliva sediments using “Genomic DNA extraction and purification Kit” (Real
Molecular Biology) following the manufacturer’s instructions. The single Val158Met (rs4680)
nucleotide polymorphism was genotyped using a TaqMan1 Drug Metabolism Genotyping
Assay on a Real Time PCR ABI Prism 7000 Sequence Detection System (APPLIED BIOSYS-
TEM, USA) in a Genomic Unit (Centro de Apoyo Tecnológico, Universidad Rey Juan Carlos,
Madrid, Spain). The 3 possible haplotypes were associated with different fluorescent dyes to
determine the identification of the different genotypes: Val/Val, Val/Met, or Met/Met. The
results were derived from a G!A substitution at the following sequence:
CCAGCGGATGGTGGATTTCGCTGGC [A/G] TGAAGGACAAGGTGTGCATGCCTGA
Data analysis
Statistical analysis was performed using SPSS software, version 21.0 (Chicago, IL, USA). Sam-
ple size was based on changes in the intensity of hand pain at 1-year follow-up as described
previously in detail [12]. An intention-to-treat analysis was conducted according to the groups
where patients were first allocated. Key baseline demographic variables were compared
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Fig 1. Flow diagram of patients throughout the course of the study.
https://doi.org/10.1371/journal.pone.0205516.g001
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between the groups using different ANOVAs for continuous data and χ2 tests of independence
for categorical data. To determine the effect of the Val158Met polymorphism, 5x2x3 repeated
measures ANCOVAs were performed with time (baseline, 1, 3, 6, 12 months) as within-subject
factor, group (physical manual therapy, surgery) and polymorphism genotype (Val/Val, Val/Met,
Met/Met) as between-subject factors, and adjustment for baseline outcomes. In addition, severity
of CTS according to EMG analysis was also included as potential covariable. The hypothesis of
interest was the 3-way interaction treatment group�Val158Met�time. Separate ANCOVAs were
performed for pain, function and symptom severity. A corrected P value of P<0.017 (Bonferroni
correction) for the 3-way interaction was required to be statistically significant.
Results
Two hundred consecutive patients with CTS were screened for eligibility criteria. One hun-
dred and twenty women (60%; mean age 47 ± 9 years old), satisfied all criteria, agreed to par-
ticipate, and were randomly allocated into physical therapy (n = 60) or surgical (n = 60)
groups. Of those in the physical therapy group, 14 had a Met/Met genotype (23%) whereas
within those in the surgery group 17 had a Met/Met genotype (28%). Fig 1 provides a flow dia-
gram of subject recruitment and retention. At one-year follow-up, 111 (92%) patients provided
follow-up data.
Baseline characteristics among the groups were similar for all variables (Table 1). Fifty-six
(93%) of the participants allocated to the surgery group received open surgery with minimal
incision. The main 3-way group interaction (treatment group�Val158Met�time) for the
repeated-measures ANCOVA was not statistically significant for the mean level of hand pain
(F = 0.60; P = 0.69), the worst pain experienced in the last week (F = 0.49; P = 0.61), function
(F = 0.12; P = 0.88) or symptom severity (F = 0.01; P = 0.98): long-term treatment outcomes
were similar in all groups independently of the Val158Met genotype. The inclusion of CTS
severity did not influence the results on any outcome (all, P>0.45). The graphical evolution of
pain, function, and symptoms severity by Val158Met genotype can be found in Figs 2 and 3.
Table 1. Baseline characteristics by treatment assignment and Val158Met polymorphism.
Physical Therapy Group (n = 60) Surgery Group (n = 60)
Val/Val (n = 21) Val/Met (n = 25) Met/Met (n = 14) Val/Val (n = 22) Val/Met (n = 21) Met/Met (n = 17)
Age (years) 45±9 47±10 46±10 47±9 48±7 46 ± 9
Years with pain 1.8±0.7 1.9±1.9 2.3±2.9 1.9±1.0 2.1±1.1 2.2±1.8
Unilateral/bilateral arm distribution n (%)
Unilateral-right side 6 (29%) 5 (20%) 2 (14%) 6 (27%) 5 (24%) 2 (12%)
Unilateral-left side 4 (19%) 2 (8%) 2 (14%) 2 (10%) 1 (5%) 1 (6%)
Bilateral symptoms 11 (42%) 18 (72%) 10 (72%) 14 (63%) 15 (71%) 14 (82%)
Severity n (%)
Minimal CTS 5 (24%) 7 (28%) 4 (28%) 5 (23%) 6 (29%) 4 (23.5%)
Moderate CTS 10 (47%) 10 (40%) 5 (36%) 10 (45%) 8 (38%) 8 (47%)
Severe CTS 6 (29%) 8 (32%) 5 (36%) 7 (32%) 7 (33%) 5 (29.5%)
Mean intensity of the pain (NPRS, 0–10) 5.2±1.5 4.8±1.6 5.1±1.0 5.2±2.2 5.6±1.5 4.7±2.6
Worst pain experienced last week (NPRS, 0–10) 6.7±1.6 6.8±1.8 5.9±1.2 7.1±2.0 7.1±1.6 6.5±2.5
Function status scale carpal tunnel syndrome (1–
5)
2.3±0.3 2.3±0.6 2.2±0.4 2.4±0.6 2.5±0.5 2.1±0.7
Severity status scale carpal tunnel syndrome (1–5) 2.3±0.5 2.6±0.7 2.4±0.6 2.7±0.7 2.8±0.6 2.6±0.7
Data are expressed as number (percentage) for categorical variables and as means ± standard deviation for continuous variables
https://doi.org/10.1371/journal.pone.0205516.t001
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Discussion
Our results showed that variations in the Val158Met genotype were not associated to long-
term treatment outcomes in pain and function in a sample of women with CTS who received
surgery or physical manual therapy. The Val158Met polymorphism has been found to modu-
late the response to therapy in some conditions; for instance, the effects of antipsychotic medi-
cation in schizophrenia and schizo-affective disorder patients [18], opioid consumption in
postoperative nephrectomy patients [19], or the efficacy of morphine in cancer patients with
pain [20]. Our study is the first one investigating the potential influence of the Val158Met
polymorphism in long-term treatment outcomes in patients with CTS. We did not find a sig-
nificant influence on the outcomes suggesting that COMT gene activity may be not as relevant
for CTS as in other conditions. In fact, our results agree with another recent study where no
genetic influence was observed in long-term treatment outcomes in individuals with chronic
low back pain [21]. It is possible that the effects of physical interventions, e.g., surgery or physi-
cal therapy, have little potential genetic influence and that the Val158Met polymorphism could
be more associated with pharmacological interventions. Future studies should investigate this
hypothesis.
Another potential explanation for the lack of influence on the outcomes may be related to
the fact that the Met allele of the Val158Met polymorphism has been associated with
Fig 2. Graphical representation of the Val158Met genotype and time on pain, function and severity symptoms in the surgery group. Error bars represent 95%
confidence interval of the mean scores.
https://doi.org/10.1371/journal.pone.0205516.g002
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augmented cortical processing in individuals with chronic pain supporting the notion that
COMT influence is more relevant in people with already heightened sensitization [22]. Since
central sensitization is a common feature of CTS not associated with electro-diagnostic find-
ings [23], it is plausible that Val158Met polymorphism modulation would be more associated
to neuro-physiological rather than to clinical outcomes. Future trials investigating the genetic
influence on changes in nociceptive pain responses in people with CTS are required.
Finally, it is interesting to note that 25% of our sample exhibited Met/Met genotype, which
agrees with previous data [11]. Yet, clinical data were not significantly different among Val/
Val, Val/Met or Met/Met genotypes, which is contrary to previous findings [11]. Future studies
including greater sample sizes are needed to further determine the role of the Val158Met poly-
morphism in CTS to confirm or refute these hypotheses.
This is the first study investigating the association of the Val158Met polymorphism and
long-term treatment outcomes in CTS, but the results should be considered based on potential
strengths and limitations which has been described previous in detail [12]. A major strength
was that we compared surgery to a well-defined non-surgical, multimodal manual therapy
approach. The physical therapy program included manual therapies that could potentially ben-
efit patients based on pain neurophysiology and current nociceptive theories of CTS. A second
strength was that multiple physiotherapists and surgeons were involved in either treatment
Fig 3. Graphical representation of the Val158Met genotype and time on pain, function and severity symptoms in the physical therapy group. Error bars represent
95% confidence interval of the mean scores.
https://doi.org/10.1371/journal.pone.0205516.g003
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group, although most patients were derived from local regional hospitals. Nevertheless, it is
important to consider that most patients received an open surgical decompression; therefore, a
comparison between surgical procedures was not possible. Third, the trial had high retention
rates at 12-month follow-up. However, we must also recognize some limitations. First, we only
included women with CTS. We do not know if the same findings would be found in men with
CTS. Second, the role of psychological variables such as depression, anxiety, or sleep disorders,
and neuro-physiological outcomes, i.e., quantitative sensory testing, has not been investigated.
Third, the optimal dosage for conservative treatment has not been established, and the out-
comes might be different with different number or frequency of treatment sessions. Finally, we
only investigated the rs4680 single nucleotide polymorphism of the Val158Met gene. Future
studies should investigate the influence of a greater number of polymorphisms in the thera-
peutic response of CTS patients.
Conclusions
The current clinical trial found that variations in the Val158Met polymorphism were not asso-
ciated with long-term changes in pain and function in women with CTS receiving surgery or
physical manual therapy.
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(COMT) gene polymorphisms are associated with baseline disability but not long-term treatment out-
come in patients with chronic low back pain. Eur Spine J. 2015; 24: 2425–31. https://doi.org/10.1007/
s00586-015-3866-5 PMID: 25772090
22. Vossen H, Kenis G, Rutten a B, van Os J, Hermens H, Lousberg R. The genetic influence on the cortical
processing of experimental pain and the moderating effect of pain status. PLoS One. 2010; 5: e13641.
https://doi.org/10.1371/journal.pone.0013641 PMID: 21049025
23. De-la-Llave-Rincón AI, Fernández-de-las-Peñas C, Laguarta-Val S, Alonso-Blanco C, Martı́nez-Pérez
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